These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35167738)

  • 1. Interlaboratory Comparison Study (Ring Test) of Next-Generation Sequencing-Based NTRK Fusion Detection in South Korea.
    Lee SE; Lee MS; Jeon YK; Shim HS; Kang J; Kim J; Choi YL
    Cancer Res Treat; 2023 Jan; 55(1):28-40. PubMed ID: 35167738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
    Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
    Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion Detection.
    Bormann Chung C; Lee J; Barritault M; Bringuier PP; Xu Z; Huang WY; Beharry A; Castillo J; Christiansen J; Lin JC; Sheffield BS
    J Mol Diagn; 2022 Jan; 24(1):18-32. PubMed ID: 34656759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CANTRK: A Canadian Ring Study to Optimize Detection of NTRK Gene Fusions by Next-Generation RNA Sequencing.
    Stockley TL; Lo B; Box A; Corredor AG; DeCoteau J; Desmeules P; Feilotter H; Grafodatskaya D; Greer W; Hawkins C; Huang WY; Izevbaye I; Lépine G; Martins Filho SN; Papadakis AI; Park PC; Riviere JB; Sheffield BS; Spatz A; Spriggs E; Tran-Thanh D; Yip S; Zhang T; Torlakovic E; Tsao MS
    J Mol Diagn; 2023 Mar; 25(3):168-174. PubMed ID: 36586421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer.
    Schraa SJ; Stelloo E; Laclé MM; Swennenhuis JF; Brosens LAA; Fijneman RJA; Feitsma H; Koopman M; de Leng WW; Vink GR; Bol GM
    Virchows Arch; 2023 Jun; 482(6):983-992. PubMed ID: 37067589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays.
    Kirchner M; Glade J; Lehmann U; Merkelbach-Bruse S; Hummel M; Lehmann A; Trautmann M; Kumbrink J; Jung A; Dietmaier W; Endris V; Kazdal D; Ploeger C; Evert M; Horst D; Kreipe H; Kirchner T; Wardelmann E; Büttner R; Weichert W; Dietel M; Schirmacher P; Stenzinger A; Pfarr N
    Genes Chromosomes Cancer; 2020 Aug; 59(8):445-453. PubMed ID: 32319699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
    Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
    Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical instructions for testing and targeted therapy in adult patients with solid tumours with NTRK gene fusion in common clinical practice.
    Büchler T; Dundr P; Fínek J; Kiss I; Matěj R; Melichar B; Michal M; Petruželka L
    Klin Onkol; 2020; 33(6):414-419. PubMed ID: 33685189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
    Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
    Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
    Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
    Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
    Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
    Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of RNA-Based Next-Generation Sequencing Assays for the Detection of NTRK Gene Fusions.
    Park HJ; Baek I; Cheang G; Solomon JP; Song W
    J Mol Diagn; 2021 Nov; 23(11):1443-1451. PubMed ID: 34756276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
    Solomon JP; Linkov I; Rosado A; Mullaney K; Rosen EY; Frosina D; Jungbluth AA; Zehir A; Benayed R; Drilon A; Hyman DM; Ladanyi M; Sireci AN; Hechtman JF
    Mod Pathol; 2020 Jan; 33(1):38-46. PubMed ID: 31375766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence
    Fu Y; Li Z; Gao F; Yang J; Wu H; Zhang B; Pu X; Fan X
    Front Oncol; 2021; 11():669197. PubMed ID: 33996597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTRK gene aberrations in triple-negative breast cancer: detection challenges using IHC, FISH, RT-PCR, and NGS.
    Zito Marino F; Buono S; Montella M; Giannatiempo R; Messina F; Casaretta G; Arpino G; Vita G; Fiorentino F; Insabato L; Sgambato A; Orditura M; Franco R; Accardo M
    J Pathol Clin Res; 2023 Sep; 9(5):367-377. PubMed ID: 37143440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays.
    Pfarr N; Kirchner M; Lehmann U; Leichsenring J; Merkelbach-Bruse S; Glade J; Hummel M; Stögbauer F; Lehmann A; Trautmann M; Kumbrink J; Jung A; Dietmaier W; Endris V; Kazdal D; Evert M; Horst D; Kreipe H; Kirchner T; Wardelmann E; Lassen U; Büttner R; Weichert W; Dietel M; Schirmacher P; Stenzinger A
    Genes Chromosomes Cancer; 2020 Mar; 59(3):178-188. PubMed ID: 31652375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus Recommendations to Optimize the Detection and Reporting of
    Stockley TL; Lo B; Box A; Gomez Corredor A; DeCoteau J; Desmeules P; Feilotter H; Grafodatskaya D; Hawkins C; Huang WY; Izevbaye I; Lepine G; Papadakis AI; Park PC; Sheffield BS; Tran-Thanh D; Yip S; Sound Tsao M
    Curr Oncol; 2023 Mar; 30(4):3989-3997. PubMed ID: 37185415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.
    Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D
    Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.